KALV - カ―ビラン・セラピュ―ティクス (KalVista Pharmaceuticals Inc.) カ―ビラン・セラピュ―ティクス

 KALVのチャート


 KALVの企業情報

symbol KALV
会社名 KalVista Pharmaceuticals Inc (カ―ビラン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 KalVista Pharmaceuticals Inc. formerly Carbylan Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery development and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate KVD818 is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.   カ―ビラン・セラピュ―ティクスは、米国のバイオ医薬品会社。満たされていない医療ニ―ズに対応する併用療法の開発と商業化に焦点を当て事業を展開する。変形性膝関節症に関連する痛みを治療するための医薬品として、関節内注射用製品候補であるハイドロス-TAを提供する。本社所在地はカリフォルニア州。   KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with a Phase 2 clinical trial expected to initiate in the second quarter of 2021. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
本社所在地 55 Cambrigge Parkway Suite 901E Cambridge MA 02142 USA
代表者氏名 Richard Aldrich リチャード・アルドリッチ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 857-999-0075
設立年月日 38047
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 33人
url www.kalvista.com
nasdaq_url https://www.nasdaq.com/symbol/kalv
adr_tso
EBITDA EBITDA(百万ドル) -20.06300
終値(lastsale) 17.465
時価総額(marketcap) 300043233.455
時価総額 時価総額(百万ドル) 339.64240
売上高 売上高(百万ドル) 12.01600
企業価値(EV) 企業価値(EV)(百万ドル) 291.78640
当期純利益 当期純利益(百万ドル) -15.90700
決算概要 決算概要 BRIEF: For the three months ended 31 July 2018 Kalvista Pharmaceuticals Inc revenues increased from $96K to $3.7M. Net loss increased 2% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.5M to $8.4M (expense) General and administrative increase of 14% to $2.4M (expense).

 KALVのテクニカル分析


 KALVのニュース

   KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Legal & General Group Plc  2021/11/01 08:44:41 Dakota Financial News
Legal & General Group Plc boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 47.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,452 shares of the specialty pharmaceutical companys stock after purchasing an additional 786 shares during the quarter. Legal & General Group []
   Hedge Funds Are Cashing Out Of KalVista Pharmaceuticals, Inc. (KALV)  2021/10/29 12:47:29 Insider Monkey
   BlackRock Inc. Reduces Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)  2021/10/24 08:18:41 Transcript Daily
BlackRock Inc. lessened its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 8.5% during the 2nd quarter, Holdings Channel reports. The firm owned 1,426,422 shares of the specialty pharmaceutical company’s stock after selling 133,066 shares during the quarter. BlackRock Inc. owned about 0.06% of KalVista Pharmaceuticals worth $34,178,000 as of its most recent filing […]
   Brokerages Anticipate KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to Post -$0.78 Earnings Per Share  2021/10/22 18:28:41 Transcript Daily
Analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report earnings of ($0.78) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for KalVista Pharmaceuticals earnings, with estimates ranging from ($0.92) to ($0.71). KalVista Pharmaceuticals posted earnings per share of ($0.58) during the same quarter last year, which indicates a negative []
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference  2021/09/21 11:03:00 FinanzNachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today ann…
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2021/08/09 11:04:00 FinanzNachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista''s board of directors granted four newly-hired employees inducement options to purchase an
   Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)  2021/07/20 02:32:11 Insider Monkey
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results  2021/07/13 10:33:00 FinanzNachrichten
- FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 - - FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 - KalVista Pharmaceuticals,
   KalVista Pharma''s KVD900 slows progression, accelerates resolution of attacks in HAE patients  2021/07/12 12:15:40 Seeking Alpha
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)  2021/06/28 11:04:00 FinanzNachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today ann
   Hedge Funds Are Crazy About KalVista Pharmaceuticals, Inc. (KALV)  2021/07/20 02:32:11 Insider Monkey
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results  2021/07/13 10:33:00 FinanzNachrichten
- FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 - - FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 - KalVista Pharmaceuticals,
   KalVista Pharma''s KVD900 slows progression, accelerates resolution of attacks in HAE patients  2021/07/12 12:15:40 Seeking Alpha
   KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)  2021/06/28 11:04:00 FinanzNachrichten
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today ann
   Form 8-K KalVista Pharmaceuticals For- Jun 05  2021/06/10 23:43:44 StreetInsider
Form 8-K KalVista Pharmaceuticals For: Jun 05 StreetInsider.com

 関連キーワード  (医薬品 米国株 カ―ビラン・セラピュ―ティクス KALV KalVista Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)